Application of MBL in preparing drug for preventing or treating disease induced by effector T cell
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology for treating effects and diseases, applied in metabolic diseases, skin diseases, bone diseases, etc., to achieve the effect of strong regeneration ability and rich sources
Active Publication Date: 2017-08-18
XINXIANG MEDICAL UNIV
View PDF3 Cites 2 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, whether there are still unknown factors that promote the inhibitory effect of Treg cells needs to be further developed and studied urgently
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0031] Experimental Materials
[0032] 1. Source of cells used in the experiment
[0033] Newborn umbilical cord blood was collected from the third affiliated hospital of Xinxiang Medical College and the full-term healthy newborns of the Department of Obstetrics and Gynecology of Xinxiang First People's Hospital. The blood was collected from the placenta umbilical vein immediately after delivery and put into a blood collection bag containing 28 mL of preservation solution. All blood samples were delivered to the laboratory within 4 hours after sampling.
[0034] 2. Main reagents
[0035] The medium RPMI1640, Fetal bovine serum (FBS), and 10×PBS solution were all purchased from ThermoFisher Scientific.
[0036] Lymphocyte separation solution (Ficoll-Paque PLUS) is a sterile endotoxin test solution (<0.12EU / mL) of FicollTM PM400 and sodium diatrizoate with a density of 1.077 g / mL, purchased from GE Healthcare Life Sciences.
[0104] 1. Preparation of cord blood mononuclear cells
[0105] Reference example 1
[0106] 2. Coated with anti-CD3mAb
[0107] Reference example 1
[0108] 3. Magnetic sorting of CD4+CD25-T cells and CD4+CD25+T cells
[0109] Sample preparation
[0110] Density gradient centrifugation was used to separate peripheral mononuclear cells. In order to remove platelets, the cells were resuspended in a buffer and centrifuged at 200×g for 10-15 minutes. The supernatant was carefully aspirated and washed repeatedly.
[0111] Magnetic labeling of non-CD4+ T cells
[0112] The entire process should be completed quickly and the cells should be kept in a pre-cooled state to pre...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention discloses an application of MBL in preparing a drug for preventing or treating disease induced by an effector T cell and belongs to the technical field of a novel application of mannan binding lectin. The key point of the technical scheme is as follows: the invention relates to the application of MBL in preparing a drug for preventing or treating infectious diseases, autoimmune diseases or/and allergic diseases induced by the effector T cell, wherein MBL realizes functions of the drug by enhancing iTreg cell and inhibiting proliferation of the effector T cell. Through researches, a novel factor of adjusting the inhibition function of the Tregs cell is obtained, that is, MBL directly enhances the inhibition action of the Tregs cell on proliferation of the effector T cell. The application disclosed by the invention highlights a novel function of MBL, and MBL not only plays an important anti-infection role in inherent immunity, but also can be a pertinent target spot for treating various autoimmune diseases and inflammatory diseases in intervention of the function of the Tregs cell.
Description
Technical field [0001] The invention relates to the technical field of new uses of mannan-binding lectins, in particular to the application of MBL in the preparation of drugs for preventing or treating effector T cell-induced diseases. Background technique [0002] Mannan-binding lectin (mannan-binding lectin, MBL) is a highly conserved plasma protein mainly secreted by hepatocytes, and is a member of the collectins family in the C-type lectin superfamily. MBL is also an acute phase reactive protein, and its plasma concentration can increase by 2-3 times during stress (such as pathogen infection, surgery, etc.). MBL, known as the ante-antibody, uses its carbohydrate recongnition domain (CRD) to broadly recognize sugar structures on the surface of a variety of pathogens such as bacteria, viruses, parasites, and fungi, including D-mannose. Sugar, L-fucose, N-acetylglucosamine, N-acetylmannosamine, etc. Its collagen-like region (CLR) binds to MBL-associated serine protease (MBL-MA...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more